Summit Therapeutics

World & Business

FDA turns down Summit’s lung cancer drug after survival result falls short

Ivonescimab plus chemotherapy delayed progression but did not demonstrate a statistically significant overall-survival improvement in the primary analysis.

RE

BL

OP

7 Sources, 42m ago, first seen 42m ago

Science

AstraZeneca invests $2 billion in Summit Therapeutics

STAT reports the companies are teaming up to test ivonescimab, a PD-1/VEGF bispecific drug, alongside AstraZeneca’s antibody-drug conjugates.

ST

1 Source, 47d ago, first seen 47d ago

World & Business

Summit Therapeutics stock surges after AstraZeneca reveals $2 billion investment

Barron's says the deal would give AstraZeneca exposure to a cancer treatment it describes as promising, without buying Summit outright.

BA

BL

2 Sources, 47d ago, updated 47d ago

Summit Therapeutics

Recent posts

FDA turns down Summit’s lung cancer drug after survival result falls short

AstraZeneca invests $2 billion in Summit Therapeutics

Summit Therapeutics stock surges after AstraZeneca reveals $2 billion investment

Summit Therapeutics

Recent posts

FDA turns down Summit’s lung cancer drug after survival result falls short

AstraZeneca invests $2 billion in Summit Therapeutics

Summit Therapeutics stock surges after AstraZeneca reveals $2 billion investment